Clinical Testing News and Research

RSS

TIC10 may improve usefulness of TRAIL protein in cancer therapy

A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.

9 Feb 2013

TB vaccine candidate trial results are 'landmark' in fight against disease

"Today marks an important landmark for the fight against tuberculosis (TB)," with the publication in the Lancet of clinical trial results showing the TB vaccine candidate MVA85A "was no more effective in protecting infants from developing pulmonary TB than" the standard Bacillus Calmette-Guerin (BCG) vaccine, Peggy Johnston, senior program officer at the Bill & Melinda Gates Foundation, writes in the foundation's "Impatient Optimists" blog.

6 Feb 2013

Effective therapy needed for chronic fatigue syndrome patients

Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA).

25 Jan 2013

Over-expression of NEK2 in cancer cells significantly enhances drug resistance

Increased NEK2 gene expression linked to increased drug resistance, faster cancer growth, and poorer patient outcome - The finding may improved diagnostic and prognostic tools for cancer care and could lead to improved cancer therapies

16 Jan 2013

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Mayo Clinic researchers identify new target to improve treatment of pancreatic cancer

Researchers at Mayo Clinic in Florida have identified a new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more than 95 percent of pancreatic cancer cases. This fast-growing, often lethal cancer is resistant to conventional chemotherapy.

4 Jan 2013

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health Systems a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia (AML).

27 Dec 2012

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.

11 Dec 2012

Combination of diagnostic tests can predict conversion from MCI to Alzheimer's

A combination of diagnostic tests, including imaging and cerebrospinal fluid biomarkers can improve prediction of conversion from mild cognitive impairment (MCI) to Alzheimer's disease, according to a new study published online in the journal Radiology.

11 Dec 2012

BlueGenics aims to discover new drugs from deep sea to combat osteoporosis

Searching for substances from the deep sea to combat osteoporosis and other human common diseases is one of the objectives of the new European research project "BlueGenics" which has received funding of EUR 6 million from the European Commission.

10 Dec 2012

Advance Study to evaluate safety and benefit of DBS-f for patients with mild Alzheimer's

The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.

7 Dec 2012

Cook receives FDA approval for Zilver PTX Drug-Eluting Peripheral Stent to treat PAD

The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked as a result of peripheral artery disease (PAD).

15 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

Positive results from Palatin’s bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

9 Nov 2012

New partnership to make advancements in personalized breast cancer treatment and care

The Edith Sanford Breast Cancer Foundation and The Scripps Research Institute today announced the formation of a dynamic partnership that will lay the groundwork for lifesaving advancements in personalized breast cancer treatment and care.

3 Nov 2012

Study shows reduced risk of liver-related mortality in African American women with HIV/HCV

A new study shows that African American women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are less likely to die from liver disease than Caucasian or Hispanic women. Findings in the November issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, indicate that lower liver-related mortality in African American women was independent of other causes of death.

1 Nov 2012

African American women coinfected with HIV and HCV less likely to die from liver disease than Caucasian or Hispanic women

31 Oct 2012

HIV agent offers HER2-positive breast cancer hope

A drug used to treat HIV infection may be a new treatment line for patients with an aggressive type of breast cancer, US researchers believe.

15 Oct 2012

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.